Skip to main content

Teva Pharmaceutical Value Stock - Dividend - Research Selection

Teva pharmaceutical

ISIN: US8816242098 , WKN: 883035

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. This segment also develops, manufactures, and sells active pharmaceutical ingredients. The Specialty Medicines segment provides specialty medicines for use in central nervous system and respiratory indications. Its products in the central nervous system area comprise Copaxone for the treatment of relapsing forms of MS; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. This segment\'s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Qnasl, Braltus, Cinqair/Cinqaero, and Aerivio Spiromax for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. The company has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q4 2025 Update

2026-03-11
Duquesne Family Office’s Q4 2025 13F: top holdings, new stakes, big adds/cuts, and exits in Amazon, Alphabet, Natera & more—read now.

Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

2026-03-10
Teva Pharmaceutical Industries Limited (TEVA) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:00 AM EDTCompany ParticipantsRichard...

Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript

2026-03-09

Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.

2026-03-05

Piper Sandler Reiterates Overweight on Teva Pharmaceutical Indus, Raises Price Target to $41

2026-03-04
Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target from $40 to $41.

Teva Pharmaceutical Industries' Teva Pharmaceuticals And Funds Managed By Blackstone Life Sciences Reveal A $400M Strategic Funding Agreement Spread Across Four Years To Support The Continued Clinical Development Of Duvakitug

2026-03-03
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences ("BXLS") today announced a $400 million strategic funding agreement spread

Baron Health Care Fund Q4 2025 Contributors And Detractors

2026-03-03

What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd?

2026-03-02

Allspring Smid Cap Growth Fund Q4 2025 Top Contributors And Detractors

2026-02-26

FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application

2026-02-23
FDA accepts Teva's application for the monthly schizophrenia injection TEV-749 as shares show mixed momentum signals.